acute myeloid leukemia (AML)

Dr. Hetty Caraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her fellowship in medical oncology at Johns Hopkins University in Baltimore. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is currently a Staff Physician at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic.

Valeria Santini is an Associate Professor of Hematology at the University of Florence Medical School in Florence Italy, where she received her degree in Medicine and Postgraduate diploma in hematology (cum laude). She worked as an EORTC fellow in experimental hematology from 1988 to 1991 at the Dr. den Hoed Kliniek, Erasmus University, Rotterdam. In 1999 she worked in the Department of Leukemia at MD Anderson Cancer Center, University of Texas, Houston.

Dr. Navada is an assistant professor in the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York City.  She attended medical school at the University of Illinois at Chicago.  Subsequently, she did an Internal Medicine Residency at the University of Michigan in Ann Arbor prior to completing a hematology/oncology fellowship at Mount Sinai.  She is currently completing a Masters of Science in

Joachim Deeg, MD is a member of the Fred Hutchinson Cancer Research Center in Seattle, Washington and professor of medicine at the University of Washington. He is also a member of the AA&MDSIF Medical Advisory Board.

Dr. Graubert’s research focuses on the molecular pathogenesis of myeloid leukemias. While at Washington University in St. Louis, he and his colleagues used genome sequencing technology extensively to gain insights into the genetic basis of human cancer and to use this information to improve risk stratification tools and identify targets for novel therapy.  Their group published the first complete genome sequence of a human cancer (